Results & Expectations
    Retatrutide

    Retatrutide 6-Month Results

    At 6 months, retatrutide patients have crossed the halfway mark and the transformation is unmistakable. Most have lost 17-22% of their body weight -- results that rival bariatric surgery without the operating room.

    Published: April 3, 202613 min read

    Six months on retatrutide represents the midpoint of a typical treatment course, and the results at this stage are remarkable. Phase 2 data (Jastreboff et al., NEJM 2023) showed 17-22% body weight loss at the 24-week mark for patients on the higher doses -- comparable to what semaglutide achieves at its maximum over a full year. For a 250-pound patient, this means 43-55 pounds lost in just half a year, with additional weight loss still to come.

    Data Context

    Results are from Phase 2 trial data. Individual outcomes vary. Retatrutide is investigational and not FDA-approved.

    The 6-Month Transformation

    By month 6, the changes extend far beyond the scale. Patients typically report needing entirely new wardrobes, receiving comments from everyone they encounter, dramatically improved mobility and physical capacity, resolution or significant improvement of sleep apnea, reduced or eliminated diabetes medications, and a fundamentally changed relationship with food. The psychological impact can be as profound as the physical: patients who struggled with obesity for decades describe feeling like a different person.

    Metabolic Health at 6 Months

    The metabolic improvements at 6 months often exceed what weight loss alone would predict. HbA1c drops of 1.5-2.0% are common in diabetic patients. Blood pressure normalizes in many patients without medication changes. Triglycerides decrease by 25-40%. Liver fat reduction exceeds 60-80% due to glucagon-driven hepatic fat oxidation. CRP and inflammatory markers show significant reduction. These improvements represent a fundamental metabolic reset that dramatically reduces cardiovascular disease risk.

    The Weight Loss Trajectory

    Weight loss at 6 months represents approximately 70-80% of the total weight loss most patients will achieve. The rate of loss is slowing from its peak (months 2-4) but has not stopped. Months 7-12 typically add an additional 3-7% body weight loss, bringing the total to the 24% average seen at 48 weeks. Plateaus are normal and temporary -- they reflect metabolic recalibration, not treatment failure.

    Planning for the Next 6 Months

    • Reassess exercise: Your lighter body may allow higher-intensity training. Consider progressively increasing resistance training loads.
    • Body composition monitoring: A DEXA scan at 6 months provides objective data on fat vs lean mass changes.
    • Discuss maintenance: Begin conversations with your provider about long-term treatment strategy -- whether to continue, reduce dose, or plan for maintenance.
    • Address loose skin: If loose skin is developing, discuss options with your provider. Continued resistance training and adequate protein can help.

    To start your weight loss journey, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. Results based on Phase 2 data (Jastreboff et al., NEJM 2023). Individual results vary. Consult a healthcare provider.

    Start Your Transformation

    Semaglutide from $99/mo, tirzepatide from $125/mo. See results in months, not years.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What are typical retatrutide 6-month results?

    Retatrutide 6-month (24-week) results from phase 2 TRIUMPH-1 trial (Jastreboff et al., NEJM 2023) at the 12 mg/week maximum dose: approximately 14-17% body-weight reduction. This is at the midpoint of the 48-week trial duration; the weight-loss curve hadn't plateaued at the 24-week mark, significant rate of loss continued through week 48 (final ~24% body-weight reduction). For a 250-lb starting patient at 12 mg retatrutide: approximately 35-43 lbs lost by week 24; approximately 60 lbs lost by week 48. Lower retatrutide doses showed proportionally less weight loss at 24 weeks: 4 mg/week dose ~6-9% (~15-23 lbs for 250-lb patient); 8 mg/week dose ~10-13% (~25-33 lbs). Side effects typically improve by 6 months as dose stabilizes, nausea peaks during dose titration phase (weeks 4-12 at each dose increase) and resolves with maintenance dose stability. Comparison to FDA-approved options at similar 24-week timeframe: tirzepatide (Zepbound, Mounjaro) produces approximately 10-12% body-weight reduction at 24 weeks per SURMOUNT-1 subgroup data; semaglutide (Wegovy) produces approximately 7-9% body-weight reduction at 24 weeks per STEP 1 trial data. Retatrutide's faster trajectory at 24 weeks (~14-17% vs tirz ~10-12%, sema ~7-9%) reflects its triple-receptor mechanism (GLP-1+GIP+glucagon vs single or dual). Important caveat: retatrutide is investigational and NOT FDA-approved as of May 2026; expected FDA approval no earlier than 2027-2028 pending phase 3 readouts. For weight-loss treatment now, FDA-approved tirzepatide is the closest accessible alternative, Trimi compounded tirzepatide $125/month annual ($1,500/year all-inclusive, medication, US-licensed prescribing clinician via Arora Health 50-state network, dose changes, refills, free shipping) provides same active ingredient as brand Zepbound at substantially lower cost. Patients should NOT seek 'research peptide' retatrutide outside legitimate clinical trial enrollment.

    Phase 2: ~14-17% body-weight reduction at 24 weeks (12 mg dose).
    Loss continues through 48 weeks; not plateaued.
    Tirzepatide closest alternative now (~10-12% at 24 weeks).

    Key Takeaways

    • Retatrutide 6-month results from phase 2 TRIUMPH-1 (NEJM 2023): approximately 14-17% body-weight reduction at 24 weeks (12 mg dose).
    • Significant rate of loss continues through week 48 in phase 2 data; loss curve hadn't plateaued.
    • Side effects typically improve by 6 months as dose stabilizes; nausea peaks during titration.
    • Retatrutide is investigational and NOT FDA-approved as of May 2026; FDA-approved tirzepatide produces ~10-12% body-weight reduction at similar 24-week timeframe.
    • Trimi compounded tirzepatide $125/mo annual is closest accessible alternative, same active ingredient as brand Zepbound at substantially lower cost.

    Medically Reviewed

    DMR

    Dr. Michael Rodriguez

    MD, FACP, Board Certified in Internal Medicine

    Internal Medicine & Weight Management

    Last reviewed: November 1, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Michael Rodriguez, MD, FACP, Board Certified in Internal Medicine

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    - Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    3. Eli Lilly and Company (2025). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration.Read Study
    4. The Endocrine Society (2024). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.Read Study

    Was this article helpful?

    Keep Reading

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Retatrutide results at 6 months: expected weight loss, metabolic improvements, body composition changes, and what to expect in the second half of treatment.

    Week-by-week weight loss expectations on retatrutide. Understand the typical trajectory from first injection through 48 weeks, including acceleration phases, plateaus, and realistic weekly targets.

    What to expect after 3 months on retatrutide: typical weight loss, body changes, metabolic improvements, and how results compare to semaglutide and tirzepatide at the same timepoint.

    Start your GLP-1 journey, from $99/mo

    Get Started